Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia - PubMed (original) (raw)

. 2011 Jun 9;117(23):6247-54.

doi: 10.1182/blood-2010-10-314674. Epub 2011 Apr 11.

Sharon Horsley, Sue Colman, Kristina Anderson, Caroline Bateman, Helena Kempski, Jan Zuna, Cornelia Eckert, Vaskar Saha, Lyndal Kearney, Anthony Ford, Mel Greaves

Affiliations

Free article

Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia

Frederik W van Delft et al. Blood. 2011.

Free article

Abstract

B-cell precursor childhood acute lymphoblastic leukemia with ETV6-RUNX1 (TEL-AML1) fusion has an overall good prognosis, but relapses occur, usually after cessation of treatment and occasionally many years later. We have investigated the clonal origins of relapse by comparing the profiles of genomewide copy number alterations at presentation in 21 patients with those in matched relapse (12-119 months). We identified, in total, 159 copy number alterations at presentation and 231 at relapse (excluding Ig/TCR). Deletions of CDKN2A/B or CCNC (6q16.2-3) or both increased from 38% at presentation to 76% in relapse, suggesting that cell-cycle deregulation contributed to emergence of relapse. A novel observation was recurrent gain of chromosome 16 (2 patients at presentation, 4 at relapse) and deletion of plasmocytoma variant translocation 1 in 3 patients. The data indicate that, irrespective of time to relapse, the relapse clone was derived from either a major or minor clone at presentation. Backtracking analysis by FISH identified a minor subclone at diagnosis whose genotype matched that observed in relapse ∼ 10 years later. These data indicate subclonal diversity at diagnosis, providing a variable basis for intraclonal origins of relapse and extended periods (years) of dormancy, possibly by quiescence, for stem cells in ETV6-RUNX1(+) acute lymphoblastic leukemia.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources